Search

Displaying results 4521 - 4530 of 7283 in total
  1. Drug

    Alglucosidase alfa

    go.drugbank.com/drugs/DB01272
    ApprovedInvestigational

    Aglucosidase alfa is produced by recombinant DNA technology in a Chinese hamster ovary cell line. … Alglucosidase alfa degrades glycogen by catalyzing the hydrolysis of a-1,4- and a-1,6- glycosidic linkages of lysosomal glycogen.

  2. Drug

    Tarlatamab

    go.drugbank.com/drugs/DB17256
    ApprovedInvestigational

    Tarlatamab is a first-in-class T-cell engager used to treat extensive-stage small cell lung cancer. … [L50748] It is a bispecific monoclonal antibody that targets CD3 expressed on the surface of T-cells and delta-like ligand 3 (DLL3), an inhibitory ligand that suppresses Notch signaling and is highly expressed

  3. Drug

    Veligrotug

    go.drugbank.com/drugs/DB18976
    Approved

    [L63929] The FDA approved veligrotug-vvze on June 26, 2026, for the treatment of thyroid eye disease regardless of disease activity or duration.[L63798,L63929] … Veligrotug is a humanized IgG1 monoclonal antibody that binds the insulin-like growth factor-1 receptor and blocks ligand-induced receptor autophosphorylation, interrupting IGF-1R signaling.

  4. Drug

    Turoctocog alfa

    go.drugbank.com/drugs/DB09109
    Approved

    Turoctocog alfa is a recombinant factor VIII (rFVIII) with a truncated B-domain made from the sequence coding for 10 amino acids from the N-terminus and 11 amino acids from the C-terminus of the naturally … [A31504] It was developped by Novo Nordisk and FDA approved in October 16, 2013.[L1104]

    Products: NOVOEIGHT® 1500 UI POLVO ESTERIL PARA RECONSTITUIR A SOLUCIÓN INYECTABLE
  5. Drug

    Orlistat

    go.drugbank.com/drugs/DB01083
    ApprovedInvestigational

    It was approved by the FDA for use in combination with a reduced-calorie diet in 1999. … [A229928] Orlistat is a lipase inhibitor used in the treatment of obesity that works by inhibiting fat-metabolizing enzymes.

  6. Drug

    Bremelanotide

    go.drugbank.com/drugs/DB11653
    Approved

    [A179689] Bremelanotide was granted FDA approval on 21 June 2019.[L9635] … [A179686] The mechanism by which bremelanotide's action on receptors translates to a clinical effect is still unknown.

  7. Drug

    Defactinib

    go.drugbank.com/drugs/DB12282
    ApprovedInvestigational

    [L53208,A273943] Defactinib was approved by the US FDA in May 2025 in a co-package alongside [avutometinib] (called Avmapki Fakzynja) for the treatment of recurrent KRAS-mutated low-grade serous ovarian … Defactinib is a small molecule kinase inhibitor targeted against focal adhesion kinase (FAK) and proline-rich tyrosine kinase-2 (Pyk2), the two members of the FAK family of nonreceptor tyrosine kinases

  8. Drug

    Remimazolam

    go.drugbank.com/drugs/DB12404
    ApprovedInvestigational

    [A214852,A214857] Remimazolam was the first "soft" benzodiazepine analog to be developed[A214862] and was approved for use by the FDA in July 2020 under the brand name Byfavo.[L14722] … [A214857] These "soft drugs" are useful in the context of surgical procedures, wherein a rapid onset/offset is desirable, enabling anesthesiologists to manipulate drug concentrations as needed.

  9. Drug

    BK-MDA

    go.drugbank.com/drugs/DB12809
    Investigational

    BK-MDA has been used in trials studying the treatment of Bladder Exstrophy and Urinary Incontinence.

    Synonyms: BK-MDA
  10. Drug

    10-hydroxycamptothecin

    go.drugbank.com/drugs/DB12385
    Experimental

    10-hydroxycamptothecin is under investigation in clinical trial NCT00956787 (Study of AR-67 (DB-67) in Myelodysplastic Syndrome (MDS)).